News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
726,360 Results
Type
Article (41157)
Company Profile (264)
Press Release (684925)
Multimedia
Podcasts (85)
Webinars (20)
Section
Business (204778)
Career Advice (2027)
Deals (35557)
Drug Delivery (121)
Drug Development (81470)
Employer Resources (173)
FDA (16466)
Job Trends (14967)
News (346670)
Policy (32751)
Tag
2027 BioCapital Elite (1)
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2584)
Accelerated approval (42)
Adcomms (25)
Allergies (160)
Alliances (49595)
ALS (192)
Alzheimer's disease (1739)
Antibody-drug conjugate (ADC) (366)
Approvals (16783)
Artificial intelligence (593)
Autoimmune disease (222)
Automation (50)
Bankruptcy (362)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (201)
Biotechnology (174)
Bladder cancer (177)
Brain cancer (63)
Breast cancer (685)
Cancer (5300)
Cardiovascular disease (442)
Career advice (1716)
Career pathing (39)
CAR-T (299)
CDC (53)
Celiac Disease (2)
Cell therapy (796)
Cervical cancer (41)
Clinical research (70233)
Collaboration (1884)
Company closure (4)
Compensation (1270)
Complete response letters (69)
COVID-19 (2724)
CRISPR (98)
C-suite (973)
Cystic fibrosis (149)
Data (7038)
Decentralized trials (3)
Denatured (26)
Depression (152)
Dermatology (57)
Diabetes (549)
Diagnostics (6823)
Digital health (52)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (292)
Drug pricing (194)
Drug shortages (29)
Duchenne muscular dystrophy (265)
Earnings (91057)
Editorial (60)
Employer branding (21)
Employer resources (152)
Events (118347)
Executive appointments (1030)
FDA (19878)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (14)
Frontotemporal dementia (29)
Funding (1610)
Gene editing (210)
Generative AI (51)
Gene therapy (651)
GLP-1 (1014)
Government (4692)
Grass and pollen (6)
Guidances (396)
Healthcare (18919)
HIV (73)
Huntington's disease (52)
IgA nephropathy (91)
Immunology and inflammation (271)
Immuno-oncology (80)
Indications (157)
Infectious disease (3036)
Inflammatory bowel disease (200)
Inflation Reduction Act (14)
Influenza (128)
Intellectual property (273)
Interviews (316)
IPO (16650)
IRA (50)
Job creations (3648)
Job search strategy (1429)
JPM (58)
Kidney cancer (18)
Labor market (92)
Layoffs (553)
Leadership (34)
Legal (7953)
Liver cancer (98)
Longevity (28)
Lung cancer (712)
Lymphoma (406)
Machine learning (52)
Management (59)
Manufacturing (917)
MASH (176)
Medical device (13849)
Medtech (13926)
Mergers & acquisitions (20064)
Metabolic disorders (1406)
mRNA (173)
Multiple sclerosis (172)
NASH (17)
Neurodegenerative disease (380)
Neuropsychiatric disorders (97)
Neuroscience (3124)
Neurotech (1)
NextGen: Class of 2026 (6521)
Non-profit (4525)
Now hiring (73)
Obesity (661)
Opinion (274)
Ovarian cancer (185)
Pain (227)
Pancreatic cancer (253)
Parkinson's disease (336)
Partnered (33)
Patents (552)
Patient recruitment (587)
Peanut (60)
People (59232)
Pharmaceutical (59)
Pharmacy benefit managers (32)
Phase 1 (21888)
Phase 2 (30926)
Phase 3 (23031)
Pipeline (7093)
Policy (302)
Postmarket research (2564)
Preclinical (9280)
Press Release (64)
Prostate cancer (274)
Psychedelics (49)
Radiopharmaceuticals (302)
Rare diseases (989)
Real estate (5960)
Recruiting (70)
Regulatory (24959)
Reports (54)
Research institute (2404)
Resumes & cover letters (353)
Rett syndrome (32)
RNA editing (17)
RSV (85)
Schizophrenia (163)
Series A (266)
Series B (200)
Service/supplier (11)
Sickle cell disease (106)
Special edition (22)
Spinal muscular atrophy (164)
Sponsored (45)
Startups (3625)
State (2)
Stomach cancer (18)
Supply chain (117)
Tariffs (85)
The Weekly (57)
Vaccines (1054)
Venture capital (98)
Weight loss (420)
Women's health (109)
Worklife (19)
Date
Today (42)
Last 7 days (636)
Last 30 days (2662)
Last 365 days (29922)
2026 (7978)
2025 (30172)
2024 (35212)
2023 (40076)
2022 (51179)
2021 (55717)
2020 (54083)
2019 (46538)
2018 (35020)
2017 (32110)
2016 (31483)
2015 (37560)
2014 (31320)
2013 (26348)
2012 (28578)
2011 (29273)
2010 (27337)
Location
Africa (739)
Alabama (90)
Alaska (7)
Arizona (331)
Arkansas (13)
Asia (39453)
Australia (6452)
California (12244)
Canada (3506)
China (1224)
Colorado (522)
Connecticut (520)
Delaware (366)
Europe (85257)
Florida (1847)
Georgia (393)
Hawaii (3)
Idaho (62)
Illinois (954)
India (80)
Indiana (558)
Iowa (22)
Japan (485)
Kansas (129)
Kentucky (44)
Louisiana (38)
Maine (73)
Maryland (1481)
Massachusetts (8749)
Michigan (346)
Minnesota (674)
Mississippi (6)
Missouri (138)
Montana (33)
Nebraska (29)
Nevada (135)
New Hampshire (82)
New Jersey (3267)
New Mexico (28)
New York (3231)
North Carolina (1552)
North Dakota (8)
Northern California (6054)
Ohio (365)
Oklahoma (22)
Oregon (41)
Pennsylvania (2481)
Puerto Rico (26)
Rhode Island (50)
South America (1112)
South Carolina (76)
South Dakota (1)
Southern California (4812)
Tennessee (199)
Texas (1923)
United States (43373)
Utah (367)
Vermont (1)
Virginia (291)
Washington D.C. (80)
Washington State (980)
West Virginia (4)
Wisconsin (118)
Wyoming (2)
726,360 Results for "biomedica inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Santhera Secures Agreement with Biomedica for the Distribution of AGAMREE® (Vamorolone) in Russia
October 9, 2025
·
5 min read
Business
Oxford Biomedica Business Update
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces a business update for the year ending 31 December 2023.
December 7, 2023
·
6 min read
Deals
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that, following the announcements on 20 September and 4 December 2023, it has today completed the acquisition of ABL Europe SAS (“ABL Europe”) from Institut Mérieux SA (“Institut Mérieux”).
January 29, 2024
·
4 min read
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
September 20, 2023
·
10 min read
Business
Kyverna Therapeutics and Oxford Biomedica Sign License and Supply Agreement for LentiVector® Platform
Kyverna Therapeutics today announced a non-exclusive, multi-year license and supply agreement with Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”), a quality and innovation-led viral vector Contract and Development Manufacturing Organization (CDMO), enabling the use of LentiVector® with any Kyverna product.
September 20, 2023
·
4 min read
Business
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
Oxford Biomedica plc announces interim results for the six months ended 30 June 2023.
September 20, 2023
·
97 min read
Deals
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led cell and gene therapy CDMO, today announces that it has entered into a sale and purchase agreement (the “Agreement”) with TSGH SAS, a subsidiary of Institut Mérieux SA (“Institut Mérieux”), for the acquisition of ABL Europe SAS (“ABL Europe”) (the “Transaction”).
December 4, 2023
·
6 min read
Press Releases
Oxford Biomedica announces CFO transition
July 17, 2024
·
3 min read
BioCapital
Oxford Biomedica Implements Sapio Sciences’ Electronic Laboratory Notebook
Oxford Biomedica, a quality and innovation-led viral vector CDMO, has implemented Sapio’s Electronic Laboratory Notebook as part of its digital transformation.
July 18, 2023
·
1 min read
Press Releases
Inscobee Inc. and Apimeds, Inc. Reaffirms Appointment of New Board of Directors for Apimeds Pharmaceuticals US, Inc.
March 25, 2026
·
3 min read
1 of 72,636
Next